Rituximab maintenance therapy of follicular lymphoma in clinical practice
Abstract Standard of care for patients with symptomatic, advanced‐stage follicular lymphoma (FL) is rituximab‐containing chemoimmunotherapy followed by rituximab maintenance. This prospective, multicenter, noninterventional study analyzed how efficacy and safety data from randomized controlled trial...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-07-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.1549 |
id |
doaj-8d0721bd9e7f4b1aaea286c0d1dfc014 |
---|---|
record_format |
Article |
spelling |
doaj-8d0721bd9e7f4b1aaea286c0d1dfc0142021-09-10T10:50:38ZengWileyCancer Medicine2045-76342018-07-01772903291210.1002/cam4.1549Rituximab maintenance therapy of follicular lymphoma in clinical practiceUlrich Dührsen0Stefanie Broszeit‐Luft1Annette Dieing2Andreas Lück3Piotr Porowski4Marcel Reiser5Ulrike Schwinger6Sandra Klawitter7Katja Krumm8Kathleen Jentsch‐Ullrich9Department of Hematology University Hospital Essen Essen GermanyOncological Practice Lehrte GermanyVivantes Medical Care Center at Urban Berlin GermanyCenter for Oncology and Urology at Rostock Rostock GermanyOncological Practice Heilbronn GermanyPractice for Internal Oncology and Hematology Cologne GermanyOncological Practice Stuttgart GermanyRoche Pharma AG Grenzach‐Wyhlen GermanyRoche Pharma AG Grenzach‐Wyhlen GermanyPractice for Hematology and Oncology Magdeburg GermanyAbstract Standard of care for patients with symptomatic, advanced‐stage follicular lymphoma (FL) is rituximab‐containing chemoimmunotherapy followed by rituximab maintenance. This prospective, multicenter, noninterventional study analyzed how efficacy and safety data from randomized controlled trials translate into clinical practice in Germany. Both treatment‐naïve and relapsed/refractory patients with FL, who responded to rituximab‐containing induction and were scheduled for rituximab maintenance, were observed for 24 months. Effectiveness was measured by response and Kaplan‐Meier survival analysis. In addition, treatment patterns of induction and maintenance, as well as adverse events, were documented. The evaluable study population consisted of 310 first‐line patients and 173 relapsed/refractory patients, including 116 patients with initial Ann‐Arbor stage I/II and 20 patients with FL grade 3B. Regarding first‐line induction, a shift from R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) to R‐bendamustine was observed over time, as well as a decline in radiotherapy. 2‐year progression‐free survival rates were 88.3% (95% confidence interval [CI] 84.0‐92.6) for first‐line patients and 76.0% (95% CI: 68.8‐83.3) for relapsed/refractory patients. Conversion from partial to complete remission (PR, CR) occurred in 53.4% of analyzed first‐line patients with PR, resulting in 69.4% CRs at study end (relapsed/refractory: conversion in 42.9%, final CRs 57.9%). Safety results were consistent with the known safety profile of rituximab in this setting. Both treatment‐naïve and relapsed/refractory patients with FL show favorable 2‐year PFS rates and improvements in the remission status with postinduction rituximab monotherapy as maintenance and consolidation therapy.https://doi.org/10.1002/cam4.1549chemoimmunotherapyfollicular lymphomaobservational studyrituximab |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ulrich Dührsen Stefanie Broszeit‐Luft Annette Dieing Andreas Lück Piotr Porowski Marcel Reiser Ulrike Schwinger Sandra Klawitter Katja Krumm Kathleen Jentsch‐Ullrich |
spellingShingle |
Ulrich Dührsen Stefanie Broszeit‐Luft Annette Dieing Andreas Lück Piotr Porowski Marcel Reiser Ulrike Schwinger Sandra Klawitter Katja Krumm Kathleen Jentsch‐Ullrich Rituximab maintenance therapy of follicular lymphoma in clinical practice Cancer Medicine chemoimmunotherapy follicular lymphoma observational study rituximab |
author_facet |
Ulrich Dührsen Stefanie Broszeit‐Luft Annette Dieing Andreas Lück Piotr Porowski Marcel Reiser Ulrike Schwinger Sandra Klawitter Katja Krumm Kathleen Jentsch‐Ullrich |
author_sort |
Ulrich Dührsen |
title |
Rituximab maintenance therapy of follicular lymphoma in clinical practice |
title_short |
Rituximab maintenance therapy of follicular lymphoma in clinical practice |
title_full |
Rituximab maintenance therapy of follicular lymphoma in clinical practice |
title_fullStr |
Rituximab maintenance therapy of follicular lymphoma in clinical practice |
title_full_unstemmed |
Rituximab maintenance therapy of follicular lymphoma in clinical practice |
title_sort |
rituximab maintenance therapy of follicular lymphoma in clinical practice |
publisher |
Wiley |
series |
Cancer Medicine |
issn |
2045-7634 |
publishDate |
2018-07-01 |
description |
Abstract Standard of care for patients with symptomatic, advanced‐stage follicular lymphoma (FL) is rituximab‐containing chemoimmunotherapy followed by rituximab maintenance. This prospective, multicenter, noninterventional study analyzed how efficacy and safety data from randomized controlled trials translate into clinical practice in Germany. Both treatment‐naïve and relapsed/refractory patients with FL, who responded to rituximab‐containing induction and were scheduled for rituximab maintenance, were observed for 24 months. Effectiveness was measured by response and Kaplan‐Meier survival analysis. In addition, treatment patterns of induction and maintenance, as well as adverse events, were documented. The evaluable study population consisted of 310 first‐line patients and 173 relapsed/refractory patients, including 116 patients with initial Ann‐Arbor stage I/II and 20 patients with FL grade 3B. Regarding first‐line induction, a shift from R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) to R‐bendamustine was observed over time, as well as a decline in radiotherapy. 2‐year progression‐free survival rates were 88.3% (95% confidence interval [CI] 84.0‐92.6) for first‐line patients and 76.0% (95% CI: 68.8‐83.3) for relapsed/refractory patients. Conversion from partial to complete remission (PR, CR) occurred in 53.4% of analyzed first‐line patients with PR, resulting in 69.4% CRs at study end (relapsed/refractory: conversion in 42.9%, final CRs 57.9%). Safety results were consistent with the known safety profile of rituximab in this setting. Both treatment‐naïve and relapsed/refractory patients with FL show favorable 2‐year PFS rates and improvements in the remission status with postinduction rituximab monotherapy as maintenance and consolidation therapy. |
topic |
chemoimmunotherapy follicular lymphoma observational study rituximab |
url |
https://doi.org/10.1002/cam4.1549 |
work_keys_str_mv |
AT ulrichduhrsen rituximabmaintenancetherapyoffollicularlymphomainclinicalpractice AT stefaniebroszeitluft rituximabmaintenancetherapyoffollicularlymphomainclinicalpractice AT annettedieing rituximabmaintenancetherapyoffollicularlymphomainclinicalpractice AT andreasluck rituximabmaintenancetherapyoffollicularlymphomainclinicalpractice AT piotrporowski rituximabmaintenancetherapyoffollicularlymphomainclinicalpractice AT marcelreiser rituximabmaintenancetherapyoffollicularlymphomainclinicalpractice AT ulrikeschwinger rituximabmaintenancetherapyoffollicularlymphomainclinicalpractice AT sandraklawitter rituximabmaintenancetherapyoffollicularlymphomainclinicalpractice AT katjakrumm rituximabmaintenancetherapyoffollicularlymphomainclinicalpractice AT kathleenjentschullrich rituximabmaintenancetherapyoffollicularlymphomainclinicalpractice |
_version_ |
1717758401429110784 |